599 related articles for article (PubMed ID: 16418784)
21. Monofluorophosphate combined with hormone replacement therapy induces a synergistic effect on bone mass by dissociating bone formation and resorption in postmenopausal women: a randomized study.
Alexandersen P; Riis BJ; Christiansen C
J Clin Endocrinol Metab; 1999 Sep; 84(9):3013-20. PubMed ID: 10487657
[TBL] [Abstract][Full Text] [Related]
22. Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis.
Finkelstein JS; Wyland JJ; Lee H; Neer RM
J Clin Endocrinol Metab; 2010 Apr; 95(4):1838-45. PubMed ID: 20164296
[TBL] [Abstract][Full Text] [Related]
23. Relationship between duration of teriparatide therapy and clinical outcomes in postmenopausal women with osteoporosis.
Lindsay R; Miller P; Pohl G; Glass EV; Chen P; Krege JH
Osteoporos Int; 2009 Jun; 20(6):943-8. PubMed ID: 18923884
[TBL] [Abstract][Full Text] [Related]
24. Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis.
Leder BZ; O'Dea LS; Zanchetta JR; Kumar P; Banks K; McKay K; Lyttle CR; Hattersley G
J Clin Endocrinol Metab; 2015 Feb; 100(2):697-706. PubMed ID: 25393645
[TBL] [Abstract][Full Text] [Related]
25. Two years of Denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial.
Leder BZ; Tsai JN; Uihlein AV; Burnett-Bowie SA; Zhu Y; Foley K; Lee H; Neer RM
J Clin Endocrinol Metab; 2014 May; 99(5):1694-700. PubMed ID: 24517156
[TBL] [Abstract][Full Text] [Related]
26. Effects of alendronate and hormone replacement therapy, alone and in combination, on bone mass and markers of bone turnover in elderly women with osteoporosis.
Eviö S; Tiitinen A; Laitinen K; Ylikorkala O; Välimäki MJ
J Clin Endocrinol Metab; 2004 Feb; 89(2):626-31. PubMed ID: 14764773
[TBL] [Abstract][Full Text] [Related]
27. Parathyroid hormone(1-84) treatment of postmenopausal women with low bone mass receiving hormone replacement therapy.
Fogelman I; Fordham JN; Fraser WD; Spector TD; Christiansen C; Morris SA; Fox J
Calcif Tissue Int; 2008 Aug; 83(2):85-92. PubMed ID: 18626566
[TBL] [Abstract][Full Text] [Related]
28. Short-term increases in bone turnover markers predict parathyroid hormone-induced spinal bone mineral density gains in postmenopausal women with glucocorticoid-induced osteoporosis.
Lane NE; Sanchez S; Genant HK; Jenkins DK; Arnaud CD
Osteoporos Int; 2000; 11(5):434-42. PubMed ID: 10912846
[TBL] [Abstract][Full Text] [Related]
29. Effects of teriparatide [rhPTH (1-34)] treatment on structural geometry of the proximal femur in elderly osteoporotic women.
Uusi-Rasi K; Semanick LM; Zanchetta JR; Bogado CE; Eriksen EF; Sato M; Beck TJ
Bone; 2005 Jun; 36(6):948-58. PubMed ID: 15878318
[TBL] [Abstract][Full Text] [Related]
30. Effects of genistein and hormone-replacement therapy on bone loss in early postmenopausal women: a randomized double-blind placebo-controlled study.
Morabito N; Crisafulli A; Vergara C; Gaudio A; Lasco A; Frisina N; D'Anna R; Corrado F; Pizzoleo MA; Cincotta M; Altavilla D; Ientile R; Squadrito F
J Bone Miner Res; 2002 Oct; 17(10):1904-12. PubMed ID: 12369794
[TBL] [Abstract][Full Text] [Related]
31. Comparison of parathyroid hormone (1-34) and elcatonin in postmenopausal women with osteoporosis: an 18-month randomized, multicenter controlled trial in China.
Li Y; Xuan M; Wang B; Yang J; Zhang H; Zhang XZ; Guo XH; Lü XF; Xue QY; Yang GY; Ji QH; Liu ZM; Li CJ; Wu TF; Sheng ZY; Li PQ; Tong JC
Chin Med J (Engl); 2013 Feb; 126(3):457-63. PubMed ID: 23422107
[TBL] [Abstract][Full Text] [Related]
32. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis.
Lindsay R; Nieves J; Formica C; Henneman E; Woelfert L; Shen V; Dempster D; Cosman F
Lancet; 1997 Aug; 350(9077):550-5. PubMed ID: 9284777
[TBL] [Abstract][Full Text] [Related]
33. Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis.
McClung MR; Wasnich RD; Recker R; Cauley JA; Chesnut CH; Ensrud KE; Burdeska A; Mills T;
J Bone Miner Res; 2004 Jan; 19(1):11-8. PubMed ID: 14753731
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of the efficacy, safety and pharmacokinetic profile of oral recombinant human parathyroid hormone [rhPTH(1-31)NH(2)] in postmenopausal women with osteoporosis.
Henriksen K; Andersen JR; Riis BJ; Mehta N; Tavakkol R; Alexandersen P; Byrjalsen I; Valter I; Nedergaard BS; Teglbjaerg CS; Stern W; Sturmer A; Mitta S; Nino AJ; Fitzpatrick LA; Christiansen C; Karsdal MA
Bone; 2013 Mar; 53(1):160-6. PubMed ID: 23234813
[TBL] [Abstract][Full Text] [Related]
35. Sequential treatment of severe postmenopausal osteoporosis after teriparatide: final results of the randomized, controlled European Study of Forsteo (EUROFORS).
Eastell R; Nickelsen T; Marin F; Barker C; Hadji P; Farrerons J; Audran M; Boonen S; Brixen K; Gomes JM; Obermayer-Pietsch B; Avramidis A; Sigurdsson G; Glüer CC
J Bone Miner Res; 2009 Apr; 24(4):726-36. PubMed ID: 19049337
[TBL] [Abstract][Full Text] [Related]
36. A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis.
Hodsman AB; Fraher LJ; Watson PH; Ostbye T; Stitt LW; Adachi JD; Taves DH; Drost D
J Clin Endocrinol Metab; 1997 Feb; 82(2):620-8. PubMed ID: 9024265
[TBL] [Abstract][Full Text] [Related]
37. Bone density after teriparatide in patients with or without prior antiresorptive treatment: one-year results from the EUROFORS study.
Minne H; Audran M; Simões ME; Obermayer-Pietsch B; Sigurðsson G; Marín F; Dalsky GP; Nickelsen T;
Curr Med Res Opin; 2008 Nov; 24(11):3117-28. PubMed ID: 18838053
[TBL] [Abstract][Full Text] [Related]
38. Prevention of femoral and lumbar bone loss with hormone replacement therapy and vitamin D3 in early postmenopausal women: a population-based 5-year randomized trial.
Komulainen M; Kröger H; Tuppurainen MT; Heikkinen AM; Alhava E; Honkanen R; Jurvelin J; Saarikoski S
J Clin Endocrinol Metab; 1999 Feb; 84(2):546-52. PubMed ID: 10022414
[TBL] [Abstract][Full Text] [Related]
39. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial.
Leder BZ; Tsai JN; Uihlein AV; Wallace PM; Lee H; Neer RM; Burnett-Bowie SA
Lancet; 2015 Sep; 386(9999):1147-55. PubMed ID: 26144908
[TBL] [Abstract][Full Text] [Related]
40. Biochemical bone markers and bone mineral density during postmenopausal hormone replacement therapy with and without vitamin D3: a prospective, controlled, randomized study.
Heikkinen AM; Parviainen M; Niskanen L; Komulainen M; Tuppurainen MT; Kröger H; Saarikoski S
J Clin Endocrinol Metab; 1997 Aug; 82(8):2476-82. PubMed ID: 9253321
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
